Why the study?
Does low-molecular-weight heparin (Kabi 2165) prevent deep-vein thrombosis in patients undergoing total hip replacement compared to adjusted-dose standard heparin?
Population
124 patients undergoing elective total hip replacement
Comparison
Low-molecular-weight heparin 2,500 anti-Xa units… vs Adjusted-dose subcutaneous standard heparin…
Design
RCT, Randomly allocated
Follow-up
Until hospital discharge
Authors
Loading...
LMWH offers comparable DVT prophylaxis to adjusted-dose heparin after hip replacement; reinforces its role as an effective alternative in orthopedic patients.
Does low-molecular-weight heparin (Kabi 2165) prevent deep-vein thrombosis in patients undergoing total hip replacement compared to adjusted-dose standard heparin?
Low-molecular-weight heparin (Kabi 2165) showed similar efficacy and safety to adjusted-dose standard heparin for DVT prophylaxis after total hip replacement.
Dechavanne et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: